Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.01
EBS's Cash-to-Debt is ranked lower than
79% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. EBS: 1.01 )
Ranked among companies with meaningful Cash-to-Debt only.
EBS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.53  Med: 2.04 Max: No Debt
Current: 1.01
Equity-to-Asset 0.62
EBS's Equity-to-Asset is ranked lower than
61% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EBS: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
EBS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.27  Med: 0.63 Max: 0.78
Current: 0.62
-1.27
0.78
Interest Coverage 10.68
EBS's Interest Coverage is ranked lower than
88% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. EBS: 10.68 )
Ranked among companies with meaningful Interest Coverage only.
EBS' s Interest Coverage Range Over the Past 10 Years
Min: 7.05  Med: 2815.62 Max: N/A
Current: 10.68
Piotroski F-Score: 4
Altman Z-Score: 3.64
Beneish M-Score: -2.37
WACC vs ROIC
11.28%
8.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.04
EBS's Operating Margin % is ranked higher than
79% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. EBS: 16.04 )
Ranked among companies with meaningful Operating Margin % only.
EBS' s Operating Margin % Range Over the Past 10 Years
Min: 10.63  Med: 16.93 Max: 25.7
Current: 16.04
10.63
25.7
Net Margin % 9.20
EBS's Net Margin % is ranked higher than
80% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. EBS: 9.20 )
Ranked among companies with meaningful Net Margin % only.
EBS' s Net Margin % Range Over the Past 10 Years
Min: 8.16  Med: 11.09 Max: 18.07
Current: 9.2
8.16
18.07
ROE % 7.42
EBS's ROE % is ranked higher than
83% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. EBS: 7.42 )
Ranked among companies with meaningful ROE % only.
EBS' s ROE % Range Over the Past 10 Years
Min: 5.5  Med: 9.3 Max: 16.93
Current: 7.42
5.5
16.93
ROA % 4.63
EBS's ROA % is ranked higher than
85% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. EBS: 4.63 )
Ranked among companies with meaningful ROA % only.
EBS' s ROA % Range Over the Past 10 Years
Min: 4.23  Med: 5.79 Max: 12.24
Current: 4.63
4.23
12.24
ROC (Joel Greenblatt) % 18.20
EBS's ROC (Joel Greenblatt) % is ranked higher than
82% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. EBS: 18.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EBS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.5  Med: 22.41 Max: 41.28
Current: 18.2
11.5
41.28
3-Year Revenue Growth Rate 5.20
EBS's 3-Year Revenue Growth Rate is ranked higher than
65% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. EBS: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EBS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 9.2 Max: 31.3
Current: 5.2
-1.1
31.3
3-Year EBITDA Growth Rate 8.80
EBS's 3-Year EBITDA Growth Rate is ranked higher than
83% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. EBS: 8.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EBS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.4 Max: 32.8
Current: 8.8
0
32.8
3-Year EPS without NRI Growth Rate 16.70
EBS's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. EBS: 16.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EBS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.7  Med: 6.65 Max: 61.7
Current: 16.7
-26.7
61.7
GuruFocus has detected 3 Warning Signs with Emergent BioSolutions Inc $EBS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EBS Guru Trades in Q1 2016

Jim Simons 1,112,811 sh (+16.94%)
Ken Fisher 457,742 sh (unchged)
Joel Greenblatt 443,728 sh (-0.70%)
Paul Tudor Jones 24,632 sh (-8.08%)
» More
Q2 2016

EBS Guru Trades in Q2 2016

Jim Simons 1,274,211 sh (+14.50%)
Joel Greenblatt 465,311 sh (+4.86%)
Ken Fisher 467,770 sh (+2.19%)
Paul Tudor Jones 16,200 sh (-34.23%)
» More
Q3 2016

EBS Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
Ken Fisher 453,870 sh (-2.97%)
Jim Simons 1,178,111 sh (-7.54%)
Joel Greenblatt 242,516 sh (-47.88%)
» More
Q4 2016

EBS Guru Trades in Q4 2016

Paul Tudor Jones 9,700 sh (New)
Ken Fisher 418,270 sh (-7.84%)
Jim Simons 883,511 sh (-25.01%)
Joel Greenblatt 165,519 sh (-31.75%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:INVA, OTCPK:BVNRY, NAS:ACOR, NAS:FPRX, NAS:ALDR, OTCPK:PFSCF, NAS:RGEN, OTCPK:MPSYY, NAS:CORT, NAS:XLRN, OTCPK:BPMUF, NAS:AMRN, NAS:INSM, NAS:INSY, NAS:FOLD, NAS:HALO, NAS:ZIOP, NAS:AMAG, NAS:LXRX, NAS:VSAR » details
Traded in other countries:ER4.Germany,
Emergent BioSolutions Inc is a specialty biopharmaceutical company operating in two divisions: Biodefense and Biosciences. Its products include BioThrax, BAT, Anthrasil, VIGIV, RSDL, NuThrax, PreviThrax and GC-072.

Emergent BioSolutions Inc was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. The Company is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and biosciences. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company's products and any product or product candidate that it acquires or successfully develop and commercialize is likely to compete with currently marketed products, such as vaccines, antibody therapies, antibiotics and other product candidates that are in development for the same indications. Specifically, the competition for its products and product candidates includes BioThrax, RSDL, BAT, AIGIV, VIGIV and PreviThrax and NuThrax. Accordingly, it is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, distribution, storage, handling, disposal and recordkeeping of these materials.

Ratios

vs
industry
vs
history
PE Ratio 31.53
EBS's PE Ratio is ranked lower than
53% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. EBS: 31.53 )
Ranked among companies with meaningful PE Ratio only.
EBS' s PE Ratio Range Over the Past 10 Years
Min: 5.26  Med: 21.08 Max: 67.2
Current: 31.53
5.26
67.2
Forward PE Ratio 17.92
EBS's Forward PE Ratio is ranked higher than
57% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. EBS: 17.92 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.20
EBS's PE Ratio without NRI is ranked lower than
73% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. EBS: 32.20 )
Ranked among companies with meaningful PE Ratio without NRI only.
EBS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.26  Med: 21.64 Max: 67.2
Current: 32.2
5.26
67.2
Price-to-Owner-Earnings 36.17
EBS's Price-to-Owner-Earnings is ranked lower than
95% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. EBS: 36.17 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EBS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.9  Med: 36.41 Max: 1470
Current: 36.17
5.9
1470
PB Ratio 2.49
EBS's PB Ratio is ranked higher than
69% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. EBS: 2.49 )
Ranked among companies with meaningful PB Ratio only.
EBS' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.8 Max: 3.61
Current: 2.49
0.8
3.61
PS Ratio 2.78
EBS's PS Ratio is ranked higher than
84% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. EBS: 2.78 )
Ranked among companies with meaningful PS Ratio only.
EBS' s PS Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.18 Max: 4.07
Current: 2.78
0.71
4.07
Price-to-Free-Cash-Flow 966.13
EBS's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. EBS: 966.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EBS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.78  Med: 23.64 Max: 1157.42
Current: 966.13
4.78
1157.42
Price-to-Operating-Cash-Flow 23.49
EBS's Price-to-Operating-Cash-Flow is ranked lower than
51% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. EBS: 23.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EBS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.45  Med: 13.23 Max: 102.3
Current: 23.49
2.45
102.3
EV-to-EBIT 14.80
EBS's EV-to-EBIT is ranked lower than
57% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. EBS: 14.80 )
Ranked among companies with meaningful EV-to-EBIT only.
EBS' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.7  Med: 13.8 Max: 38.3
Current: 14.8
1.7
38.3
EV-to-EBITDA 11.04
EBS's EV-to-EBITDA is ranked higher than
57% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. EBS: 11.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
EBS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.5  Med: 10.3 Max: 22
Current: 11.04
1.5
22
PEG Ratio 1.73
EBS's PEG Ratio is ranked lower than
85% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. EBS: 1.73 )
Ranked among companies with meaningful PEG Ratio only.
EBS' s PEG Ratio Range Over the Past 10 Years
Min: 0.82  Med: 4.02 Max: 85.06
Current: 1.73
0.82
85.06
Shiller PE Ratio 30.79
EBS's Shiller PE Ratio is ranked higher than
73% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. EBS: 30.79 )
Ranked among companies with meaningful Shiller PE Ratio only.
EBS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.28  Med: 28.64 Max: 40.87
Current: 30.79
15.28
40.87
Current Ratio 4.82
EBS's Current Ratio is ranked higher than
52% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. EBS: 4.82 )
Ranked among companies with meaningful Current Ratio only.
EBS' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 3.54 Max: 5.41
Current: 4.82
1.22
5.41
Quick Ratio 4.12
EBS's Quick Ratio is ranked lower than
53% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. EBS: 4.12 )
Ranked among companies with meaningful Quick Ratio only.
EBS' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 3.3 Max: 4.63
Current: 4.12
0.83
4.63
Days Inventory 214.46
EBS's Days Inventory is ranked lower than
70% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. EBS: 214.46 )
Ranked among companies with meaningful Days Inventory only.
EBS' s Days Inventory Range Over the Past 10 Years
Min: 87.55  Med: 124.71 Max: 209.82
Current: 214.46
87.55
209.82
Days Sales Outstanding 99.68
EBS's Days Sales Outstanding is ranked higher than
63% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. EBS: 99.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
EBS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.39  Med: 62.36 Max: 124.36
Current: 99.68
32.39
124.36
Days Payable 89.10
EBS's Days Payable is ranked higher than
71% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. EBS: 89.10 )
Ranked among companies with meaningful Days Payable only.
EBS' s Days Payable Range Over the Past 10 Years
Min: 96.33  Med: 162.25 Max: 350.8
Current: 89.1
96.33
350.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.40
EBS's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. EBS: -10.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EBS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.3  Med: -5.2 Max: -1.5
Current: -10.4
-13.3
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 10.85
EBS's Price-to-Net-Current-Asset-Value is ranked lower than
77% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. EBS: 10.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EBS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.39  Med: 6.13 Max: 20.74
Current: 10.85
3.39
20.74
Price-to-Tangible-Book 2.85
EBS's Price-to-Tangible-Book is ranked higher than
70% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. EBS: 2.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EBS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.83  Med: 2.1 Max: 3.7
Current: 2.85
0.83
3.7
Price-to-Intrinsic-Value-Projected-FCF 2.22
EBS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
61% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. EBS: 2.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EBS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 1.68 Max: 2.43
Current: 2.22
1.45
2.43
Price-to-Median-PS-Value 1.28
EBS's Price-to-Median-PS-Value is ranked lower than
65% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. EBS: 1.28 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EBS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.12 Max: 1.92
Current: 1.28
0.35
1.92
Price-to-Peter-Lynch-Fair-Value 2.27
EBS's Price-to-Peter-Lynch-Fair-Value is ranked lower than
72% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. EBS: 2.27 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
EBS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 2.49 Max: 5.95
Current: 2.27
0.57
5.95
Price-to-Graham-Number 1.67
EBS's Price-to-Graham-Number is ranked lower than
54% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. EBS: 1.67 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EBS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.48  Med: 1.24 Max: 2.44
Current: 1.67
0.48
2.44
Earnings Yield (Greenblatt) % 6.80
EBS's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. EBS: 6.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EBS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 7.2 Max: 59.3
Current: 6.8
2.6
59.3
Forward Rate of Return (Yacktman) % 15.93
EBS's Forward Rate of Return (Yacktman) % is ranked higher than
53% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. EBS: 15.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EBS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.5  Med: 2.3 Max: 18.4
Current: 15.93
-13.5
18.4

More Statistics

Revenue (TTM) (Mil) $507.1
EPS (TTM) $ 0.95
Beta1.45
Short Percentage of Float11.74%
52-Week Range $24.47 - 41.91
Shares Outstanding (Mil)40.57

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 1.67
EPS without NRI ($) 1.67
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Realpage, Anadigics, Emergent BioSolutions, ScanSource Jan 03 2016 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 

More From Other Websites
Emergent (EBS) Beats Earnings, Revenue Estimates in Q4 Feb 24 2017
Edited Transcript of EBS earnings conference call or presentation 23-Feb-17 10:00pm GMT Feb 23 2017
Emergent Biosolutions posts 4Q profit Feb 23 2017
Emergent Biosolutions posts 4Q profit Feb 23 2017
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
Emergent BioSolutions Inc Earnings Call scheduled for 5:00 pm ET today Feb 23 2017
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms... Feb 23 2017
Q4 2016 Emergent BioSolutions Inc Earnings Release - After Market Close Feb 23 2017
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 21 2017
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral... Feb 13 2017
Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a... Feb 09 2017
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum... Feb 01 2017
Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for... Jan 27 2017
Lawsuit for Investors in Shares of Emergent Biosolutions Inc (EBS) Announced by Shareholders... Jan 23 2017
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US :... Jan 12 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
Emergent Down on '17 View, Posts Preliminary '16 Results Jan 10 2017
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)